Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat + Doxorubicin in Soft Tissue Sarcomas
NCT00878800Phase 2Completed
- Sponsor
- Valerio Therapeutics
- Start
- Dec 2006
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of belinostat in soft tissue sarcoma (STS) and solid tumor, sponsored by Valerio Therapeutics. Primary endpoints: Maximum Tolerated Dose of PXD101, Maximum Tolerated Dose of Doxorubicin and 2 more. Started Dec 2006; status: completed.
02
Drugs
belinostat
03
Conditions
soft tissue sarcoma (STS)solid tumor
Beyond the preview
Go deeper on NCT00878800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00878800.